About the studies
The BE MOBILE 1 and BE MOBILE 2 studies are testing an investigational study drug called bimekizumab to see whether it is safe and effective in treating people with axial spondyloarthritis (axSpA). If you are at least 18 years of age, have nonradiographic axSpA or ankylosing spondylitis, and are not responding to treatment, you may be able to take part.*
*Other medical criteria must be met before you can join these studies; this will be assessed by the study team.